|
|
| | Carbazochrome sodium sulfonate Basic information |
| | Carbazochrome sodium sulfonate Chemical Properties |
| Melting point | approximate 210℃(dec.) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO (Sparingly), Methanol (Slightly) | | form | Solid | | color | Yellow to Dark Orange | | PH | pH (16g/l, 25℃) 5.0～6.0 | | Stability: | Hygroscopic, Moisture Sensitive, Temperature Sensitive | | InChIKey | HLFCZZKCHVSOAP-DAMYXMBDSA-M | | SMILES | C12=C/C(/C(=O)C=C1N(C(S([O-])(=O)=O)C2)C)=N\NC(=O)N.O.O.O.[Na+] | | CAS DataBase Reference | 51460-26-5(CAS DataBase Reference) |
| | Carbazochrome sodium sulfonate Usage And Synthesis |
| Chemical Properties | Carbazochrome sodium sulfonate is Yellow Solid | | Uses | Carbazochrome sodium sulfonate is a Phosphatidylinositol hydrolysis inhibitor in endothelial cells. | | Uses | Carbazochrome Sodium Sulfonate Hydrate is a phosphatidylinositol hydrolysis inhibitor in endothelial cells. | | Uses | Carbazochrome is an antihemorrhagic for use in the treatment of hemorrhoids. | | in vivo | Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of radiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats[2]. | Animal Model: | Male Sprague-Dawley rats weighing 180-230 g[2] | | Dosage: | 1, 5 and 10 mg/kg | | Administration: | I.v.; injected 30, 60, or 90 min before Ioxaglate injection (4 g I/kg, i.v.). | | Result: | Attenuated the Ioxaglate-increased vascular permeability at the dose of 1, 5 and 10 mg/kg in a dose-dependent manner, achieving statistical significance at 5 and 10 mg/kg. |
|
| | Carbazochrome sodium sulfonate Preparation Products And Raw materials |
|